News

European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus
0 Comments
It’s the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two people from Forbion, Sander Slootweg, managing partner, and Dirk Mertens, general partner. Forbion European life sciences venture capital firm Forbion, has announced the first €470M ($500M)
0 Comments
French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT).  The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development
0 Comments
A clinical stage pharma company specializing in developing nanomedicines will receive $30 million in exchange for rights to an injectable treatment for osteoarthritis (OA). In one of the largest deals in Taiwan’s biotech sector, TLC Biosciences will receive the upfront payment with potential to earn a further $110m if the treatment targeting knee pain is
0 Comments
GSK plc has announced positive headline results from its AReSVi 006 phase III trial.  AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed.  Dr Hal Barron, chief scientific officer and president, R&D, GSK, said,
0 Comments
Although the biotech industry performed strongly during the COVID-19 pandemic, it now faces challenges to valuations and access to capital. This is according to the 32nd edition of the Beyond Borders report produced by Ernst & Young LLP (EY US). The report, which EY said is a ‘moment-in-time’ snapshot of the industry, says despite the
0 Comments
Labiotech.eu has just gone global with its coverage, and now we are gearing up for the first Labiotech.eu podcast. According to Spotify, in 2021 there were 1.2 million podcasts launched. So does the world need another one? We’d like to think the answer is yes! We are trying to ensure our new podcast, Beyond Biotech,
0 Comments
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany.  The move comes as part of the company’s growth strategy.  A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational
0 Comments
Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as
0 Comments
Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has completed an oversubscribed €25M ($26.7M) Series A financing round.  Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap, which also co-led the financing that was joined by Pureos Bioventures. Ipsen
0 Comments
Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical
0 Comments
4BIO Capital, an international venture capital firm focusing on the advanced therapies sector, has co-led a $30.3M oversubscribed Series B financing in LUCA Science Inc., which is developing a novel class of mitochondria biopharmaceutical agents.  The round was co-led with DCI Partners and existing investor Fast Track Initiative, and supported by existing international investors including
0 Comments
GSK plc is set to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1B upfront payment and up to $1.2B in potential development milestones.  Affinivax is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Pneumococcal disease includes pneumonia, meningitis, bloodstream infections, and
0 Comments
Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.
0 Comments
UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has successfully raised £4.6M ($5.8M) in additional seed funding.  The financing was led by new investor Epidarex Capital with participation from existing investor the Dementia Discovery Fund (DDF). Transine said the additional funds will enable it to further develop its SINEUP
0 Comments